Современные подходы к антибактериальной терапии обострений хронической обструктивной болезни легких


https://doi.org/10.18093/0869-0189-2012-0-3-109-114

Полный текст:


Аннотация

Современные подходы к антибактериальной терапии обострений хронической обструктивной болезни легких.


Об авторе

С. Н. Авдеев
ФГУ "НИИ пульмонологии" ФМБА России
Россия

д. м. н., проф., руководитель клинического отдела 

105077, Россия, Москва, ул. 11-я Парковая, 32, корп. 4. Тел./ факс: (495) 465-52-64.



Список литературы

1. Murray C.J.L., Lopez A.D. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–1276.

2. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51: 1–16.

3. Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397–412.

4. Zielinski J., MacNee W., Wedzicha J., et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.

5. Groenewegen K.H., Schols A.M., Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467.

6. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.

7. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2011. www.goldcopd.org

8. Donaldson G.C., Wedzicha J.A. COPD exacerbations: epidemiology. Thorax 2006; 61: 164–168.

9. Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224–1238.

10. Smeeth L., Thomas S.L., Hall A.J. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004; 351: 2611–2618.

11. Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.

12. Veeramachaneni S.B., Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109–115.

13. Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.

14. Hirschmann J.V. Do bacteria cause exacerbations of COPD? Chest 2000; 118; 193–203.

15. Puhan M.A., Vollenweider D., Latshang T. et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007; 8: 30.

16. Woodhead M., Blasi F., Ewig S. et al.; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 2005; 26: 1138–1180.

17. O'Donnell D.E., Hernandez P., Kaplan A. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J. 2008; 15 (Suppl. A): 1A–8A.

18. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.

19. Celli B.R., MacNee W.; ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.

20. Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662–671.

21. Weis N., Almdal T. C-reactive protein – can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17: 88–91.

22. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664–667.

23. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Урал. мед. журн. 2008; 13: 19–24.

24. Wilson R., Jones P., Schaberg T. et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337–342.

25. Martinez F., Han M., Flaherty K., Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Exp. Rev. Anti Infect. Ther. 2006; 4: 101–124.

26. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС). Клин микробиол. антимикроб. химиотер. 2010; 12 (4): 329–341.

27. Siempos I.I., Dimopoulos G., Korbila I.P. et al. Macrolides, quinolones and amoxicillin / clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007; 29: 1127–1137.

28. Anzueto A., Fisher C.L. Jr., Busman T., Olson C.A. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin / clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 72–86.

29. Amsden G.W., Baird I.M., Simon S., Treadway G. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772–777.

30. Andre'Alves M.R., Jardim J.R., Silva R.F. et al. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J. Bras. Pneumol. 2007; 33: 43–50.

31. Rubin B.K. Immunomodulatory properties of macrolides: overview and historical perspective. Amer. J. Med. 2004; 117.(9A): 2S–4S.

32. EUCAST Expert rules in antimicrobial susceptibility testing, version 1, April 2008. http://www.EUCAST.org

33. O'Donnell J.A., Gelone S.P. The newer fluoroquinolones. Infect. Dis. Clin. N. Am. 2004; 18: 691–716.

34. Blasi F., Tarsia P., Aliberti S. et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Therap. 2006; 19: 11–19.

35. Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47: 239–242.

36. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 1994; 6: 592–599.

37. Sethi S., Fogarty C., Fulambarker A. A randomized, doubleblind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697–707.

38. Lode H., Eller J., Linnhoff A., Ioanas M. The Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur. Respir. J. 2004; 24: 947–953.

39. Wilson R., Allerga L., Huchon G. et al. Short-term and longterm outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125 (3): 953–964.

40. Geddes A.M., Klugman K.P., Rolinson G.N. Introduction: historical perspective and development of amoxicillin / clavulanate. Int. J. Antimicrob. Agents 2007; Suppl. 2: S109–S112.

41. McIvor R.A. Antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Can. Fam. Physician. 2009; 55: 15–16, 19–21.

42. Сидоренко С.В., Козлов С.Н. Группа пенициллинов. В кн.: Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. (ред.). Практическое руководство по антиинфекционной химиотерапии. М.: Боргес; 2002. 47–55.

43. Beghi G., Berni F., Carratu L. et al. Efficacy and tolerability of azithromycin versus amoxicillin clavulanic acid in acute purulent exacerbation of chronic bronchitis. J. Chemother 1995; 7: 146–152.

44. Canut A., Martιn'Herrero J.E., Labora A., Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J. Antimicrob. Chemother. 2007; 60: 605–612.

45. Llor C., Naberan K., Cots J.M. et al. Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch. Bronconeumol. 2006; 42: 175–182.

46. Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin / clavulanic acid versus the originator film-coated tablet. Int. J. Clin. Pharmacol. Ther. 2001; 39: 75–82.

47. Карпов О.И. Флемоклав Солютаб – новая лекарственная форма амоксициллина / клавуланата в лечении синусита. Клиническая фармакология и терапия 2006; 15 (4): 1–4.

48. Cortvriendt W.R., Verschoor J.S., Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung 1987; 37: 977–979.

49. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: Открытое проспективное рандомизированное исследование. Пульмонология 2008; 2: 73–80.

50. Wilson R., Anzueto A., Miravitlles M. et al. A novel study design for antibiotic trials in acute exacerbations of COPD: MAES-TRAL methodology. Int. J. COPD 2011; 6: 373–383.

51. Wilson R., Anzueto A., Miravitlles M. et al. Moxifloxacin vs amoxicillin / clavulanic acid in outpatient AECOPD: MAES-TRAL results. Eur. Respir. J. erj00903-2011; published ahead of print December 1, 2011, doi:10.1183/09031936.00090311.

52. White A.J., Gompertz S., Bayley D.L. et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–685.

53. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–2236.


Дополнительные файлы

Для цитирования: Авдеев С.Н. Современные подходы к антибактериальной терапии обострений хронической обструктивной болезни легких.  Пульмонология. 2012;(3):109-114. https://doi.org/10.18093/0869-0189-2012-0-3-109-114

For citation: Avdeev S.N. Current approach to antibacterial therapy of acute exacerbation of chronic obstructive pulmonary disease. Russian Pulmonology. 2012;(3):109-114. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-3-109-114

Просмотров: 315

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)